APOB to estimated APOB ratio for screening for the APOE2 genotype

The APOB/eAPOB ratio can be used to accurately identify the ε2/ε2 genotype and conventional risk equations are the best method for determining those at risk for ASCVD.

Authors

Institutions

Publication Details

Journal
medRxiv
Published
2026-01-30
DOI
https://doi.org/10.64898/2026.01.29.26345063
Primary Topic
Lipoproteins and Cardiovascular Health
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

APOB to estimated APOB ratio for screening for the APOE2 genotype

Anna T Wolska, Maureen Sampson, Justine Cole, Rafael Zubirán et al.
medRxiv
Lipoproteins and Cardiovascular Health
article

APOB to estimated APOB ratio for screening for the APOE2 genotype

Anna T Wolska, Maureen Sampson, Justine Cole, Rafael Zubirán, Sniderman Ad, Alan T Remaley, Claire Auger
article en

Abstract

The APOB/eAPOB ratio can be used to accurately identify the ε2/ε2 genotype and conventional risk equations are the best method for determining those at risk for ASCVD.

medRxiv
University of North Carolina at Chapel Hill (US), National Institutes of Health (US), McGill University Health Centre (CA), National Heart, Lung, and Blood Institute (US), National Institutes of Health Clinical Center (US)
U.S. Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Clinical Center
Good health and well-being
Openalex Percentile: Top 72%
Lipoproteins and Cardiovascular Health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.